Sarah A. Frech
Corporate Officer/Principal en IOMAI CORPORATION .
Perfil
Dr. Sarah A.
Frech is Vice President-Clinical Development at Intercell USA, Inc. and Vice President-Clinical Research at Vtesse, Inc.
She received her undergraduate degree from Dartmouth College, a graduate degree from the Johns Hopkins Bloomberg School of Public Health, and a doctorate degree from Washington State University.
Cargos activos de Sarah A. Frech
Empresas | Cargo | Inicio |
---|---|---|
IOMAI CORPORATION | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Sarah A. Frech.
Empresas | Cargo | Fin |
---|---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Formación de Sarah A. Frech.
Dartmouth College | Undergraduate Degree |
Washington State University | Doctorate Degree |
Johns Hopkins Bloomberg School of Public Health | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
- Bolsa de valores
- Insiders
- Sarah A. Frech